Litcius/Paper detail

Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort

Mohammad Movahedi, Elliot Hepworth, Reza Mirza, Angela Cesta, Maggie Larché, Claire Bombardier

2020Seminars in Arthritis and Rheumatism12 citationsDOI

Topics & Concepts

MedicineDiscontinuationRheumatoid arthritisAdverse effectCohortArthritisInternal medicinePhysical therapyRheumatoid Arthritis Research and TherapiesBiosimilars and Bioanalytical MethodsSpondyloarthritis Studies and Treatments
Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort | Litcius